Skip to main content

Table 3 Primary outcomes, change from baseline, intention-to-treat

From: Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]

 

Placebo (n = 16)

Fluvoxamine (n = 17)

P-value

 

Day 14

Day 42

Day 70

Day 14

Day 42

Day 70

Day 14

Day 42

Day 70

VAS Fatigue

-1.3

-0.6

-0.55

-0.3

-0.4

-0.35

0.31

0.51

0.51

FFSS

   Physical Domain

-2.0

-3.5

-4.0

0

-2.5

0

0.31

0.40

0.12

   Cognitive Domain

-1.5

1.0

0

-1.0

-1.0

0

0.69

0.85

0.60

   Social Domain

-3.0

-3.5

-2.0

-3.0

-4.0

-1.5

0.66

0.93

0.93

MFI

   General Fatigue

-2.0

0

0

0

0

-1.0

0.10

0.62

0.87

   Physical Fatigue

0

0

0

0

1.0

1.0

0.92

0.73

0.44

   Reduction Activity

0.5

-1.0

0

1.0

-0.5

1.0

0.20

0.56

0.13

   Reduction Motivation

-1.0

0

-1.0

1.0

-0.5

1.0

0.08

0.94

0.71

   Mental Fatigue

-1.0

-0.5

0

0

0

0

0.06

0.35

0.89

  1. Results are expressed as median differences in scores compared to baseline.